Works matching AU REN, ZhENggang

Results: 53

Schedule-dependent antitumor effects of 5-fluorouracil combined with sorafenib in hepatocellular carcinoma.

Published in:

2013

By:

Lifen Deng;
Zhenggang Ren;
Qingan Jia;
Weizhong Wu;
Hujia Shen;
Yanhong Wang;
Deng, Lifen;
Ren, Zhenggang;
Jia, Qingan;
Wu, Weizhong;
Shen, Hujia;
Wang, Yanhong

Publication type:

journal article

Development and Validation of a Nomogram for Patients Undergoing Transarterial Chemoembolization for Recurrent Hepatocellular Carcinoma After Hepatectomy.

Published in:

Journal of Hepatocellular Carcinoma, 2024, v. 11, p. 693, doi. 10.2147/JHC.S444682

By:

Diyang Xie;
Zhongchen Li;
Jia Yuan;
Xin Yin;
Rongxin Chen;
Lan Zhang;
Zhenggang Ren

Publication type:

Article

Retrospective analysis of transcatheter arterial chemoembolization treatment for spontaneously ruptured hepatocellular carcinoma.

Published in:

Oncology Letters, 2019, v. 18, n. 6, p. 6423, doi. 10.3892/ol.2019.11037

By:

Zou, Jixue;
Li, Chao;
Chen, Yi;
Chen, Rongxin;
Xue, Tongchun;
Xie, Xiaoying;
Zhang, Lan;
Ren, Zhenggang

Publication type:

Article

Arsenic trioxide and sorafenib combination therapy for human hepatocellular carcinoma functions via up‑regulation of TNF‑related apoptosis‑inducing ligand.

Published in:

Oncology Letters, 2018, v. 16, n. 3, p. 3341, doi. 10.3892/ol.2018.8981

By:

Wang, Lingyan;
Min, Zhihui;
Wang, Xiangdong;
Hu, Mushuang;
Song, Dongli;
REN, ZhENggang;
ChENg, YunfENg;
Wang, Yanhong

Publication type:

Article

Peripheral blood neutrophil count as a prognostic factor for patients with hepatocellular carcinoma treated with sorafenib.

Published in:

Molecular & Clinical Oncology, 2017, v. 7, n. 5, p. 837, doi. 10.3892/mco.2017.1416

By:

JIA YUAN;
HONGMING LIANG;
JINGHUAN LI;
MIAO LI;
BEI TANG;
HUI MA;
XIAOYING XIE;
XIN YIN;
LAN ZHANG;
ZHENGGANG REN

Publication type:

Article

Lipiodolized transarterial chemoembolization in hepatocellular carcinoma patients after curative resection.

Published in:

Journal of Cancer Research & Clinical Oncology, 2013, v. 139, n. 5, p. 773, doi. 10.1007/s00432-012-1343-7

By:

Chen, Xiaohong;
Zhang, Boheng;
Yin, Xin;
Ren, Zhenggang;
Qiu, Shuangjian;
Zhou, Jian

Publication type:

Article

Phase 2 study of serplulimab with the bevacizumab biosimilar HLX04 in the first-line treatment of advanced hepatocellular carcinoma.

Published in:

Cancer Immunology, Immunotherapy, 2025, v. 74, n. 2, p. 1, doi. 10.1007/s00262-024-03917-w

By:

Ren, Zhenggang;
Shao, Guoliang;
Shen, Jie;
Zhang, Li;
Zhu, Xu;
Fang, Weijia;
Sun, Guoping;
Bai, Yuxian;
Wu, Jianbing;
Liu, Lianxin;
Yuan, Yuan;
Zhang, Jingdong;
Li, Zhen;
Zhang, Ling;
Yin, Tao;
Wu, Jincai;
Hou, Xiaoli;
Yu, Haoyu;
Li, Jing;
Wang, Qingyu

Publication type:

Article

SAFFRON-104: a phase Ib/II study of sitravatinib alone or with tislelizumab in advanced hepatocellular carcinoma and gastric cancer/gastroesophageal junction cancer.

Published in:

Cancer Immunology, Immunotherapy, 2024, v. 73, n. 11, p. 1, doi. 10.1007/s00262-024-03806-2

By:

Li, Jin;
Bai, Yuxian;
Chen, Zhendong;
Ying, Jieer;
Guo, Yabing;
Fang, Weijia;
Zhang, Feng;
Xiong, Jianping;
Zhang, Tao;
Meng, Zhiqiang;
Zhang, Jingdong;
Ren, Zhenggang;
Hao, Chunyi;
Chen, Yajin;
Lin, Xiaoyan;
Pan, Hongming;
Zhou, Fuxiang;
Li, Xin;
Yu, Fan;
Zhang, Juan

Publication type:

Article

Activated hepatic stellate cells promote epithelial-to-mesenchymal transition in hepatocellular carcinoma through transglutaminase 2-induced pseudohypoxia.

Published in:

Communications Biology, 2018, v. 1, n. 1, p. N.PAG, doi. 10.1038/s42003-018-0177-5

By:

Ma, Hui;
Xie, Liqi;
Zhang, Lan;
Yin, Xin;
Jiang, Hucong;
Xie, Xiaoying;
Chen, Rongxin;
Lu, Haojie;
Ren, Zhenggang

Publication type:

Article

Higher Matrix Stiffness Upregulates Osteopontin Expression in Hepatocellular Carcinoma Cells Mediated by Integrin β1/GSK3β/β-Catenin Signaling Pathway.

Published in:

PLoS ONE, 2015, v. 10, n. 8, p. 1, doi. 10.1371/journal.pone.0134243

By:

You, Yang;
Zheng, Qiongdan;
Dong, Yinying;
Wang, Yaohui;
Zhang, Lan;
Xue, Tongchun;
Xie, Xiaoying;
Hu, Chao;
Wang, Zhiming;
Chen, Rongxin;
Wang, Yanhong;
Cui, Jiefeng;
Ren, Zhenggang

Publication type:

Article

Identification of HBV-MLL4 Integration and Its Molecular Basis in Chinese Hepatocellular Carcinoma.

Published in:

PLoS ONE, 2015, v. 10, n. 4, p. 1, doi. 10.1371/journal.pone.0123175

By:

Dong, Hua;
Zhang, Lan;
Qian, Ziliang;
Zhu, Xuehua;
Zhu, Guanshan;
Chen, Yunqin;
Xie, Xiaoying;
Ye, Qinghai;
Zang, Jie;
Ren, Zhenggang;
Ji, Qunsheng

Publication type:

Article

Transarterial Chemoembolization (TACE) Combined with Sorafenib in Treatment of HBV Background Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Propensity Score Matching Study.

Published in:

BioMed Research International, 2019, p. 1, doi. 10.1155/2019/2141859

By:

Yuan, Jia;
Yin, Xin;
Tang, Bei;
Ma, Hui;
Zhang, Lan;
Li, Lixin;
Chen, Rongxin;
Xie, Xiaoying;
Ren, Zhenggang

Publication type:

Article

Camrelizumab Combined with FOLFOX4 Regimen as First-Line Therapy for Advanced Hepatocellular Carcinomas: A Sub-Cohort of a Multicenter Phase Ib/II Study.

Published in:

Drug Design, Development & Therapy, 2021, v. 15, p. 1873, doi. 10.2147/DDDT.S304857

By:

Li, Hui;
Qin, Shukui;
Liu, Ying;
Chen, Zhendong;
Ren, Zhenggang;
Xiong, Jianping;
Meng, Zhiqiang;
Zhang, Xiao;
Wang, Linna;
Zhang, Xiaojing;
Zou, Jianjun

Publication type:

Article

Caveolin-1 Confers Resistance of Hepatoma Cells to Anoikis by Activating IGF-1 Pathway.

Published in:

Cellular Physiology & Biochemistry (Karger AG), 2015, v. 36, n. 3, p. 1223, doi. 10.1159/000430292

By:

Tang, Wenqing;
Feng, Xuemei;
Zhang, Si;
Ren, Zhenggang;
Liu, Yinkun;
Yang, Biwei;
lv, Bei;
Cai, Yu;
Xia, Jinglin;
Ge, Ningling

Publication type:

Article

Expression and Clinical Significance of MPS-1 in Hepatocellular Carcinoma.

Published in:

International Journal of General Medicine, 2021, v. 14, p. 9145, doi. 10.2147/IJGM.S334378

By:

Jiang, He;
Yuan, Feifei;
Zhao, Zhiying;
Xue, Tongchun;
Ge, Ningling;
Ren, Zhenggang;
Zhang, Lan

Publication type:

Article

IMbrave 151: a randomized phase II trial of atezolizumab combined with bevacizumab and chemotherapy in patients with advanced biliary tract cancer.

Published in:

Therapeutic Advances in Medical Oncology, 2021, p. 1, doi. 10.1177/17588359211036544

By:

Hack, Stephen P.;
Verret, Wendy;
Mulla, Sohail;
Liu, Bo;
Wang, Yulei;
Macarulla, Teresa;
Ren, Zhenggang;
El-Khoueiry, Anthony B.;
Zhu, Andrew X.

Publication type:

Article

Matrix stiffness‐mediated effects on macrophages polarization and their LOXL2 expression.

Published in:

FEBS Journal, 2021, v. 288, n. 11, p. 3465, doi. 10.1111/febs.15566

By:

Xing, Xiaoxia;
Wang, Yaohui;
Zhang, Xi;
Gao, Xiangyu;
Li, Miao;
Wu, Sifan;
Zhao, Yan;
Chen, Jie;
Gao, Dongmei;
Chen, Rongxin;
Ren, Zhenggang;
Zhang, Kezhi;
Cui, Jiefeng

Publication type:

Article

IDO and intra-tumoral neutrophils were independent prognostic factors for overall survival for hepatocellular carcinoma.

Published in:

2019

By:

Wang, Yan;
Yao, Rongrong;
Zhang, Lan;
Xie, Xiaoying;
Chen, Rongxin;
Ren, Zhenggang

Publication type:

journal article

JS-K, a novel non-ionic diazeniumdiolate derivative, inhibits Hep 3B hepatoma cell growth and induces c-Jun phosphorylation via multiple MAP kinase pathways.

Published in:

Journal of Cellular Physiology, 2003, v. 197, n. 3, p. 426, doi. 10.1002/jcp.10380

By:

Zhenggang Ren;
Siddhartha Kar;
Ziqiu Wang;
Meifang Wang;
Joseph E. Saavedra;
Brian I. Carr

Publication type:

Article

Randomized Phase 3 LEAP-012 Study: Transarterial Chemoembolization With or Without Lenvatinib Plus Pembrolizumab for Intermediate-Stage Hepatocellular Carcinoma Not Amenable to Curative Treatment.

Published in:

CardioVascular & Interventional Radiology, 2022, v. 45, n. 4, p. 405, doi. 10.1007/s00270-021-03031-9

By:

Llovet, Josep M.;
Vogel, Arndt;
Madoff, David C.;
Finn, Richard S.;
Ogasawara, Sadahisa;
Ren, Zhenggang;
Mody, Kalgi;
Li, Jerry J.;
Siegel, Abby B.;
Dubrovsky, Leonid;
Kudo, Masatoshi

Publication type:

Article

Case Series of Steroid-Resistant Immune Checkpoint Inhibitor Associated Myocarditis: A Comparative Analysis of Corticosteroid and Tofacitinib Treatment.

Published in:

Frontiers in Pharmacology, 2021, v. 12, p. 1, doi. 10.3389/fphar.2021.770631

By:

Wang, Cong;
Lin, Jinyi;
Wang, Yan;
Hsi, David H.;
Chen, Jiahui;
Liu, Tianshu;
Zhou, Yuhong;
Ren, Zhenggang;
Zeng, Zhaochong;
Cheng, Leilei;
Ge, Junbo

Publication type:

Article

Analysis by Treatment Period and Liver Function in EMERALD-1: Phase 3 Study of Durvalumab (D) With/Without Bevacizumab (B) With Transarterial Chemoembolization (TACE) in Unresectable Hepatocellular Carcinoma (uHCC) Eligible for Embolization.

Published in:

Journal of Oncology Navigation & Survivorship, 2024, v. 15, n. 10, p. 327

By:

Chan, Stephen L.;
Kudo, Masatoshi;
Decaens, Thomas;
Erinjeri, Joseph P.;
Qin, Shukui;
Ren, Zhenggang;
Arai, Yasuaki;
Bouattour, Mohamed;
Breder, Valeriy V.

Publication type:

Article

Camrelizumab plus oxaliplatin‐based chemotherapy as first‐line therapy for advanced biliary tract cancer: A multicenter, phase 2 trial.

Published in:

International Journal of Cancer, 2021, v. 149, n. 11, p. 1944, doi. 10.1002/ijc.33751

By:

Chen, Xinni;
Qin, Shukui;
Gu, Shanzhi;
Ren, Zhenggang;
Chen, Zhendong;
Xiong, Jianping;
Liu, Ying;
Meng, Zhiqiang;
Zhang, Xiao;
Wang, Linna;
Zhang, Xiaojing;
Zou, Jianjun

Publication type:

Article

A glucose-enriched lung pre-metastatic niche triggered by matrix stiffness-tuned exosomal miRNAs in hepatocellular carcinoma.

Published in:

Nature Communications, 2025, v. 16, n. 1, p. 1, doi. 10.1038/s41467-025-56878-8

By:

Zhao, Yingying;
Yu, Hongmei;
Li, Jiajun;
Qian, Jiali;
Li, Miao;
Zhang, Xi;
Wang, Mimi;
Wang, Yaohui;
Dong, Yinying;
You, Yang;
Zhou, Qiwen;
Gao, Dongmei;
Zhao, Yan;
Liu, Binbin;
Chen, Rongxin;
Ren, Zhenggang;
Wang, Zhiming;
Zhang, Kezhi;
Cui, Jiefeng

Publication type:

Article

IMbrave 151: a randomized phase II trial of atezolizumab combined with bevacizumab and chemotherapy in patients with advanced biliary tract cancer.

Published in:

Therapeutic Advances in Medical Oncology, 2021, p. 1, doi. 10.1177/17588359211036544

By:

Hack, Stephen P.;
Verret, Wendy;
Mulla, Sohail;
Liu, Bo;
Wang, Yulei;
Macarulla, Teresa;
Ren, Zhenggang;
El-Khoueiry, Anthony B.;
Zhu, Andrew X.

Publication type:

Article

A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma.

Published in:

Therapeutic Advances in Medical Oncology, 2019, v. 11, p. N.PAG, doi. 10.1177/1758835919889001

By:

Qin, Shukui;
Chan, Stephen Lam;
Sukeepaisarnjaroen, Wattana;
Han, Guohong;
Choo, Su Pin;
Sriuranpong, Virote;
Pan, Hongming;
Yau, Thomas;
Guo, Yabing;
Chen, Minshan;
Ren, Zhenggang;
Xu, Jianming;
Yen, Chia-Jui;
Lin, Zhong-Zhe;
Manenti, Luigi;
Gu, Yi;
Sun, Yongjian;
Tiedt, Ralph;
Hao, Lu;
Song, Wenjie

Publication type:

Article

NLRP3/IL‐1β induced myeloid‐derived suppressor cells recruitment and PD‐L1 upregulation promotes oxaliplatin resistance of hepatocellular carcinoma.

Published in:

MedComm, 2023, v. 4, n. 6, p. 1, doi. 10.1002/mco2.447

By:

Liu, Wenfeng;
Zhang, Feng;
Quan, Bing;
Yao, Fan;
Chen, Rongxin;
Ren, Zhenggang;
Yin, Xin

Publication type:

Article

ID1 overexpression promotes HCC progression by amplifying the AURKA/Myc signaling pathway.

Published in:

International Journal of Oncology, 2020, v. 57, n. 3, p. 845, doi. 10.3892/ijo.2020.5092

By:

Wu, Man;
Zhou, Yuhong;
Fei, Chengming;
Chen, Tianyi;
Yin, Xin;
Zhang, Lan;
Ren, Zhenggang

Publication type:

Article

Development and Preliminary Validation of a Novel Convolutional Neural Network Model for Predicting Treatment Response in Patients with Unresectable Hepatocellular Carcinoma Receiving Hepatic Arterial Infusion Chemotherapy.

Published in:

Journal of Digital Imaging, 2024, v. 37, n. 4, p. 1282, doi. 10.1007/s10278-024-01003-2

By:

Quan, Bing;
Li, Jinghuan;
Mi, Hailin;
Li, Miao;
Liu, Wenfeng;
Yao, Fan;
Chen, Rongxin;
Shan, Yan;
Xu, Pengju;
Ren, Zhenggang;
Yin, Xin

Publication type:

Article

Real-world study of hepatic artery infusion chemotherapy combined with anti-PD-1 immunotherapy for hepatocellular carcinoma patients with portal vein tumor thrombus.

Published in:

Therapeutic Advances in Medical Oncology, 2024, p. 1, doi. 10.1177/17588359241231252

By:

Li, Jinghuan;
Quan, Bing;
Liu, Wenfeng;
Zhao, Menglong;
Yao, Fan;
Chen, Rongxin;
Ren, Zhenggang;
Yin, Xin

Publication type:

Article

Randomised Phase 1b/2 trial of tepotinib vs sorafenib in Asian patients with advanced hepatocellular carcinoma with MET overexpression.

Published in:

2021

By:

Ryoo, Baek-Yeol;
Cheng, Ann-Li;
Ren, Zhenggang;
Kim, Tae-You;
Pan, Hongming;
Rau, Kun-Ming;
Choi, Hye Jin;
Park, Joong-Won;
Kim, Jee Hyun;
Yen, Chia Jui;
Lim, Ho Yeong;
Zhou, Dongli;
Straub, Josef;
Scheele, Juergen;
Berghoff, Karin;
Qin, Shukui

Publication type:

journal article

Activation of Piezo1 contributes to matrix stiffness‐induced angiogenesis in hepatocellular carcinoma.

Published in:

Cancer Communications, 2022, v. 42, n. 11, p. 1162, doi. 10.1002/cac2.12364

By:

Li, Miao;
Zhang, Xi;
Wang, Mimi;
Wang, Yaohui;
Qian, Jiali;
Xing, Xiaoxia;
Wang, Zhiming;
You, Yang;
Guo, Kun;
Chen, Jie;
Gao, Dongmei;
Zhao, Yan;
Zhang, Lan;
Chen, Rongxin;
Cui, Jiefeng;
Ren, Zhenggang

Publication type:

Article

The prognostic significance of microRNA-221 in hepatocellular carcinoma: An updated meta-analysis.

Published in:

International Journal of Biological Markers, 2021, v. 36, n. 3, p. 40, doi. 10.1177/17246008211032689

By:

Liu, Wenfeng;
Hu, Keshu;
Zhang, Feng;
Lu, Shenxin;
Chen, Rongxin;
Ren, Zhenggang;
Yin, Xin

Publication type:

Article

Predicting Disease-Specific Survival for Patients With Primary Cholangiocarcinoma Undergoing Curative Resection by Using a Decision Tree Model.

Published in:

Frontiers in Oncology, 2022, v. 12, p. 1, doi. 10.3389/fonc.2022.824541

By:

Quan, Bing;
Li, Miao;
Lu, Shenxin;
Li, Jinghuan;
Liu, Wenfeng;
Zhang, Feng;
Chen, Rongxin;
Ren, Zhenggang;
Yin, Xin

Publication type:

Article

First-Line Systemic Treatment Strategies for Unresectable Hepatocellular Carcinoma: A Systematic Review and Network Meta-Analysis of Randomized Clinical Trials.

Published in:

Frontiers in Oncology, 2021, v. 11, p. 1, doi. 10.3389/fonc.2021.771045

By:

Liu, Wenfeng;
Quan, Bing;
Lu, Shenxin;
Tang, Bei;
Li, Miao;
Chen, Rongxin;
Ren, Zhenggang;
Yin, Xin

Publication type:

Article

Safety and efficacy of lenvatinib by starting dose based on body weight in patients with unresectable hepatocellular carcinoma in REFLECT.

Published in:

2021

By:

Okusaka, Takuji;
Ikeda, Kenji;
Kudo, Masatoshi;
Finn, Richard;
Qin, Shukui;
Han, Kwang-Hyub;
Cheng, Ann-Lii;
Piscaglia, Fabio;
Kobayashi, Masahiro;
Sung, Max;
Chen, Minshan;
Wyrwicz, Lucjan;
Yoon, Jung-Hwan;
Ren, Zhenggang;
Mody, Kalgi;
Dutcus, Corina;
Tamai, Toshiyuki;
Ren, Min;
Hayato, Seiichi;
Kumada, Hiromitsu

Publication type:

journal article

γ-Glutamyltranspeptidase is a Prognostic Marker of Survival and Recurrence in Radiofrequency-Ablation Treatment of Hepatocellular Carcinoma.

Published in:

Annals of Surgical Oncology: An Oncology Journal for Surgeons, 2014, v. 21, n. 9, p. 3084, doi. 10.1245/s10434-014-3724-4

By:

Ma, Hui;
Zhang, Lan;
Tang, Bei;
Wang, Yan;
Chen, Rongxin;
Zhang, Boheng;
Chen, Yi;
Ge, Ningling;
Wang, Yanhong;
Gan, Yuhong;
Ye, Shenglong;
Ren, Zhenggang

Publication type:

Article

Prognostic Significance of Alpha-fetoprotein Status in the Outcome of Hepatocellular Carcinoma after Treatment of Transarterial Chemoembolization.

Published in:

Annals of Surgical Oncology: An Oncology Journal for Surgeons, 2012, v. 19, n. 11, p. 3540, doi. 10.1245/s10434-012-2368-5

By:

Wang, Yan;
Chen, Yi;
Ge, Ningling;
Zhang, Lan;
Xie, Xiaoying;
Zhang, Jubo;
Chen, Rongxin;
Wang, Yanhong;
Zhang, Boheng;
Xia, Jinglin;
Gan, Yuhong;
Ren, Zhenggang;
Ye, Shenglong

Publication type:

Article

The Significance of MMP-9 Over MMP-2 in HCC Invasiveness and Recurrence of Hepatocellular Carcinoma After Curative Resection.

Published in:

Annals of Surgical Oncology: An Oncology Journal for Surgeons, 2012, v. 19, p. 375, doi. 10.1245/s10434-011-1836-7

By:

Chen, Rongxin;
Cui, Jiefeng;
Xu, Changde;
Xue, Tongchun;
Guo, Kun;
Gao, Dongmei;
Liu, Yinkun;
Ye, Shenglong;
Ren, Zhenggang

Publication type:

Article

Matrix stiffness-upregulated LOXL2 promotes fibronectin production, MMP9 and CXCL12 expression and BMDCs recruitment to assist pre-metastatic niche formation.

Published in:

Journal of Experimental & Clinical Cancer Research (17569966), 2018, v. 37, n. 1, p. N.PAG, doi. 10.1186/s13046-018-0761-z

By:

Wu, Sifan;
Zheng, Qiongdan;
Xing, Xiaoxia;
Dong, Yinying;
Wang, Yaohui;
You, Yang;
Chen, Rongxin;
Hu, Chao;
Chen, Jie;
Gao, Dongmei;
Zhao, Yan;
Wang, Zhiming;
Xue, Tongchun;
Ren, Zhenggang;
Cui, Jiefeng

Publication type:

Article

Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab: data derived from a multicenter phase 2 trial.

Published in:

Journal of Hematology & Oncology, 2020, v. 13, n. 1, p. 1, doi. 10.1186/s13045-020-00886-2

By:

Wang, Feng;
Qin, Shukui;
Sun, Xinchen;
Ren, Zhenggang;
Meng, Zhiqiang;
Chen, Zhendong;
Chai, Xiaoli;
Xiong, Jianping;
Bai, Yuxian;
Yang, Lin;
Zhu, Hong;
Fang, Weijia;
Lin, Xiaoyan;
Chen, Xiaoming;
Li, Enxiao;
Wang, Linna;
Yan, Ping;
Zou, Jianjun

Publication type:

Article

Higher matrix stiffness as an independent initiator triggers epithelial-mesenchymal transition and facilitates HCC metastasis.

Published in:

Journal of Hematology & Oncology, 2019, v. 12, n. 1, p. 1, doi. 10.1186/s13045-019-0795-5

By:

Dong, Yinying;
Zheng, Qiongdan;
Wang, Zhiming;
Lin, Xiahui;
You, Yang;
Wu, Sifan;
Wang, Yaohui;
Hu, Chao;
Xie, Xiaoying;
Chen, Jie;
Gao, Dongmei;
Zhao, Yan;
Wu, Weizhong;
Liu, Yinkun;
Ren, Zhenggang;
Chen, Rongxin;
Cui, Jiefeng

Publication type:

Article

Extrapolating Prognostic Factors of Primary Curative Resection to Postresection Recurrences Hepatocellular Carcinoma Treatable by Radiofrequency Ablation.

Published in:

Gastroenterology Research & Practice, 2021, p. 1, doi. 10.1155/2021/8878417

By:

Ma, Hui;
Li, Zhongchen;
Yuan, Jia;
Zhang, Lan;
Xie, Xiaoying;
Yin, Xin;
Chen, Rongxin;
Ren, Zhenggang

Publication type:

Article

A Phase 3 Study of Pembrolizumab versus Placebo for Previously Treated Patients from Asia with Hepatocellular Carcinoma: Health-Related Quality of Life Analysis from KEYNOTE-394.

Published in:

Liver Cancer (2235-1795), 2024, v. 13, n. 4, p. 389, doi. 10.1159/000535338

By:

Qin, Shukui;
Fang, Weijia;
Ren, Zhenggang;
Ou, Shuangyan;
Lim, Ho Yeong;
Zhang, Feng;
Lee, Kin Chung;
Choi, Hye Jin;
Tong, Jiandong;
Tao, Min;
Xu, Aibing;
Cheng, Ashley;
Lu, Chang-Hsien;
Chiu, Chang-Fang;
Wahid, Mohamed Ibrahim Abdul;
Kamble, Shital;
Norquist, Josephine M.;
Zhong, Wenyan;
Li, Chen;
Chen, Zhendong

Publication type:

Article

Hepatocellular Carcinoma Patients with Hepatitis B Virus Infection Exhibited Favorable Survival from Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.

Published in:

Liver Cancer (2235-1795), 2024, v. 13, n. 4, p. 344, doi. 10.1159/000534446

By:

Du, Qi;
Yuan, Jia;
Ren, Zhenggang

Publication type:

Article

Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2022 Edition).

Published in:

Liver Cancer (2235-1795), 2023, v. 12, n. 5, p. 405, doi. 10.1159/000530495

By:

Zhou, Jian;
Sun, Huichuan;
Wang, Zheng;
Cong, Wenming;
Zeng, Mengsu;
Zhou, Weiping;
Bie, Ping;
Liu, Lianxin;
Wen, Tianfu;
Kuang, Ming;
Han, Guohong;
Yan, ZhiPing;
Wang, Maoqiang;
Liu, Ruibao;
Lu, Ligong;
Ren, Zhenggang;
Zeng, ZhaoChong;
Liang, Ping;
Liang, Changhong;
Chen, Min

Publication type:

Article

Phase 2 Study of the PD-1 Inhibitor Serplulimab plus the Bevacizumab Biosimilar HLX04 in Patients with Previously Treated Advanced Hepatocellular Carcinoma.

Published in:

Liver Cancer (2235-1795), 2023, v. 12, n. 2, p. 1, doi. 10.1159/000526638

By:

Ren, Zhenggang;
Shao, Guoliang;
Shen, Jie;
Zhang, Li;
Zhu, Xu;
Fang, Weijia;
Sun, Guoping;
Bai, Yuxian;
Wu, Jianbing;
Liu, Lianxin;
Yuan, Yuan;
Zhang, Jingdong;
Li, Zhen;
Zhang, Ling;
Yin, Tao;
Wu, Jincai;
Hou, Xiaoli;
Wang, Qingyu;
Zhu, Jun;
Fan, Jia

Publication type:

Article

Tislelizumab in Patients with Previously Treated Advanced Hepatocellular Carcinoma (RATIONALE-208): A Multicenter, Non-Randomized, Open-Label, Phase 2 Trial.

Published in:

Liver Cancer (2235-1795), 2023, v. 12, n. 1, p. 72, doi. 10.1159/000527175

By:

Ren, Zhenggang;
Ducreux, Michel;
Abou-Alfa, Ghassan K.;
Merle, Philippe;
Fang, Weijia;
Edeline, Julien;
Li, Zhiwei;
Wu, Lihua;
Assenat, Eric;
Hu, Sheng;
Rimassa, Lorenza;
Zhang, Tao;
Blanc, Jean-Frédéric;
Pan, Hongming;
Ross, Paul;
Yen, Chia-Jui;
Tran, Albert;
Shao, Guoliang;
Bouattour, Mohamed;
Chen, Yajin

Publication type:

Article

A Phase 2 Study of Camrelizumab for Advanced Hepatocellular Carcinoma: Two-Year Outcomes and Continued Treatment beyond First RECIST-Defined Progression.

Published in:

Liver Cancer (2235-1795), 2021, v. 10, n. 5, p. 500, doi. 10.1159/000516470

By:

Ren, Zhenggang;
Qin, Shukui;
Meng, Zhiqiang;
Chen, Zhendong;
Chai, Xiaoli;
Xiong, Jianping;
Bai, Yuxian;
Yang, Lin;
Zhu, Hong;
Fang, Weijia;
Lin, Xiaoyan;
Chen, Xiaoming;
Li, Enxiao;
Wang, Linna;
Yan, Ping;
Zou, Jianjun

Publication type:

Article

A Phase 2 Study of Camrelizumab for Advanced Hepatocellular Carcinoma: Two-Year Outcomes and Continued Treatment beyond First RECIST-Defined Progression.

Published in:

Liver Cancer (2235-1795), 2021, v. 10, n. 5, p. 500, doi. 10.1159/000516470

By:

Ren, Zhenggang;
Qin, Shukui;
Meng, Zhiqiang;
Chen, Zhendong;
Chai, Xiaoli;
Xiong, Jianping;
Bai, Yuxian;
Yang, Lin;
Zhu, Hong;
Fang, Weijia;
Lin, Xiaoyan;
Chen, Xiaoming;
Li, Enxiao;
Wang, Linna;
Yan, Ping;
Zou, Jianjun

Publication type:

Article